Abstract
The proteome is fundamental to human biology and health but little is known about ancestral diversity of its genetic determinants. In GWAS of plasma levels of 2,923 proteins in 3,974 Chinese adults, we identified pQTLs for 1,784 proteins, including 1,312 cis-pQTLs for 1,264 proteins. Fine-mapping identified 3,475 credible sets for independent pQTLs, 36% of which were distinct from those identified in European adults as assessed by three different methods. In phenome-wide MR analyses, 59 disease associations were in strong LD (r2>0.95) with a cis-pQTL sentinel variant, including 26 with strong evidence of colocalisation (PP.H4>0.9) and 34 not identified in previous similar European studies. Evaluation of current drug development identified 8 confirmed therapeutic targets, 8 potential repurposing targets, and 19 potential novel targets (13 not previously reported in Europeans). The findings demonstrate the importance of extending proteogenomic studies to non-European ancestry populations to identify potential novel drug targets for major diseases.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The CKB baseline survey and the first re-survey were supported by the Kadoorie Charitable Foundation in Hong Kong. The long-term follow-up and subsequent resurveys have been supported by Wellcome grants to Oxford University (212946/Z/18/Z, 202922/Z/16/Z, 104085/Z/14/Z, 088158/Z/09/Z) and grants from the National Natural Science Foundation of China (82192901, 82192904, 82192900) and from the National Key Research and Development Program of China (2016YFC0900500).The UK Medical Research Council (MC_UU_00017/1, MC_UU_12026/2, MC_U137686851), Cancer Research UK (C16077/A29186, C500/A16896) and the British Heart Foundation (CH/1996001/9454), provide core funding to the Clinical Trial Service Unit and Epidemiological Studies Unit at Oxford University for the project. The proteomic assays were supported by BHF (18/23/33512), Novo Nordisk, and Olink. DNA extraction and genotyping were supported by GlaxoSmithKline and the UK Medical Research Council (MC-PC-13049, MC-PC-14135). Computation used the Oxford Biomedical Research Computing (BMRC) facility, a joint development between the Wellcome Centre for Human Genetics and the Big Data Institute supported by Health Data Research UK and the NIHR Oxford Biomedical Research Centre; the views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical Review Committee of the Chinese Centre for Disease Control and Prevention (Beijing, China) gave ethical approval for this work Oxford Tropical Research Ethics Committee, University of Oxford (Oxford, UK) gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
